Clinical trial
Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients…
NCT00396357 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00396357 |
|---|---|
| Title | Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone |
| Official title | A Multicenter, Double-blind, Randomized Parallel-group, Study to Demonstrate the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd as add-on to Metformin 500 mg Bid Compared to Metformin 1000 mg Bid in Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Vildagliptin, metformin |
| Enrollment | 914 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2008 |
| First posted | Nov 6, 2006 |
| Last update posted | Dec 17, 2020 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: